Belite Bio (BLTE) | Stock Overview & Key Data
Belite Bio Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $200.00 on February 3, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Belite Bio
BLTE
|
6.44B Mid-cap | -3.42% | -11.18% | -18.26% | -9.59% | -13.84% | 122.26% | 740.70% | 264.27% | 309.84% | 855.47% | 855.47% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | -21.90% | -17.38% | -12.35% | 49.84% | -2.61% | 807.83% | 2,210.03% | 21.08% | -16.07% | -16.07% | -16.07% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | -0.45% | 4.37% | 42.32% | 57.95% | 30.66% | 122.97% | 216.35% | 282.39% | 2,961.10% | 2,485.23% | 2,485.23% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 5.74% | -7.11% | -10.77% | -20.32% | -14.75% | 6.78% | -37.73% | -51.28% | 86.91% | 161.27% | 281.12% |
Ownership & Short Interest
Calculate Your Belite Bio Investment Returns
Long-Term Investment Performance Analysis
Belite Bio stock price in May 2016 was $35.18, A $1,000.00 lump sum investment in Belite Bio made 10 years ago would be worth approximately $3,900.80 today, representing a outstanding return of 290.08%. This translates to an annualized return (CAGR) of 14.57%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BLTE's 52-week high and low?
- In the last 52 weeks, Belite Bio reached a high of $200.00 (on February 3, 2026) and a low of $56.10 (on July 2, 2025).
- What is the market cap and P/E ratio for BLTE?
- Curious about Belite Bio's size and valuation? Its market capitalization stands at 6.44B. When it comes to valuation, the P/E ratio (trailing twelve months) is -69.65, and the forward P/E (looking ahead) is 205.43.
- Does BLTE pay dividends? If so, what's the yield?
- As for dividends, Belite Bio isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Belite Bio's main competitors or similar companies to consider before investing?
When looking at Belite Bio, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Praxis Precision
PRAX9.60B Healthcare Biotechnology 807.83% 2,210.03% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 122.97% 216.35% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.78% -37.73% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Belite Bio, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Belite Bio's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -16.94%, the Debt to Equity ratio from the most recent quarter is 0.06, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for BLTE?
- Looking at Belite Bio's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of BLTE stock is held by insiders and institutions?
- Wondering who owns Belite Bio stock? Company insiders (like executives and directors) hold about 44.43% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 18.71%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.